NCT04700683已完成不适用
Chronic Efficacy and Usability of Transcutaneous Electrical Nerve Stimulation in Subjects With Restless Leg Syndrome (RLS)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 6
- 主要终点
- Evaluate the clinical tolerability, usability, and patient response for the prototype device, with the intention of improving overall device performance.
研究概览
简要总结
Prospective multi-site randomized sham-controlled crossover feasibility study evaluating tolerability and efficacy of noninvasive peripheral nerve stimulation (NPNS) for patients with moderate-severe primary Restless Legs Syndrome (RLS). Response to NPNS investigational device was compared to sham control in a 2x2 crossover design such that subjects were assigned to receive 2 weeks of NPNS and 2 weeks of sham, in randomized order.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Device Feasibility
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has moderate-severe RLS symptoms as defined by a score of 15 or greater points on IRLS.
- •RLS symptoms are primarily noticeable in the subject's lower legs and/or feet.
- •Subject reports having a medical diagnosis of primary idiopathic restless legs syndrome (RLS) or Willis-Ekbom Disorder (WED) OR Investigator has diagnosed the subject with primary idiopathic restless legs syndrome (RLS) or Willis-Ekbom Disorder (WED).
- •Subject has experienced RLS symptoms at night on 2 or more nights per week during the previous month.
- •On typical dose and schedule of RLS medication (if any), subject typically experiences RLS symptoms on 2 or more nights per week.
- •RLS symptoms are primarily in the evening and night.
- •Subject owns the necessary equipment to respond to texts, phone calls, and video calls.
- •Subject is 18 years of age or older when written informed consent is obtained.
- •Subject has signed a valid, Institutional Review Board (IRB)-approved informed consent form, can understand the requirements of the study and instructions for device usage, and can converse in English.
排除标准
- •Subject has RLS that is known to be caused by another diagnosed condition.
- •Subject has active implantable medical devices anywhere in the body (including pacemakers), or passive medical devices implanted in the leg.
- •Subject has an uncontrolled sleep disorder other than RLS that significantly interferes with their sleep as determined by the trial director or physician.
- •Subject has been diagnosed with one of the following conditions: Epilepsy or other seizure disorder, Cellulitis or open sores of the legs, Renal failure, Iron-Deficiency Anemia, Severe movement disorder symptoms (Parkinson's disease, Huntington's disease, dyskinesia, dystonia), Deep Vein Thrombosis, Stage 4-5 Chronic Kidney Disease, Multiple sclerosis, Current, active or acute or chronic infection other than viral upper respiratory tract infections, A malignancy within the past 5 years (not including basal or squamous cell skin cancer)
- •Subject is on dialysis or anticipated to start dialysis while participating in the study
- •Subject is allergic to electrode gel, polyurethane foam, or lycra.
- •Subject has severe edema in lower legs.
- •Subject has failed a nerve conduction study prescribed by a physician or has been diagnosed with severe peripheral neuropathy.
- •During Visit 1, subject cannot notice the stimulation at the maximal dose or cannot tolerate the stimulation at the minimal effective dose
- •Subject selects Statement 2 or is unable to decide which of the following two statements most closely describe their condition: Statement 1: My symptoms are best characterized by a strong or overwhelming urge to move my legs. Moving my legs often results in temporary relief of that urge. Statement 2: My symptoms are best characterized by involuntary leg spasms that happen at regular intervals. These leg spasms can wake me up in the middle of the night."
- •Subject has significantly changed medication dose or schedule of antidepressants, sleep medications, or RLS medications within the past 30 days.
- •Recent history of alcohol or recreational drug abuse (within the past 6 months).
- •Subject has received an investigational drug or device within the last 30 days or is planning to receive an investigational device during the duration of the study.
- •Subject has undergone a major surgery (excluding dental work) in the previous 30 days.
- •Subject has another medical condition that may affect validity of the study or put the subject at risk as determined by the investigator.
- •Subject is unable or unwilling to comply with study requirements
结局指标
主要结局
Evaluate the clinical tolerability, usability, and patient response for the prototype device, with the intention of improving overall device performance.
时间窗: Weeks 1-2 of each intervention
Subject satisfaction and usability questionnaire
次要结局
- Change from baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) score at week 2(Week 2 of each intervention compared to week prior to study entry)
- Change to Summary NRS score of RLS symptom severity(Weeks 1-2 of each intervention)
- Responder rate on CGI-I scale at week 2 relative to baseline(Week 2 of each intervention compared to week prior to study entry)
- Change to Daily NRS score of RLS symptom severity(Weeks 1-2 of each intervention)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Treating Depression With Transcutaneous Electrical Cranial-auricular Acupoint Stimulation (TECAS).Mild-to-moderate DepressionNCT03909217The University of Hong Kong470
已完成
4 期
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva TreatmentPost-Menopausal OsteoporosisNCT00551174Hoffmann-La Roche781
招募中
不适用
Transcutaneous Electrical Acustimulation in the Treatment of Mild to Moderate Ulcerative ColitisUlcerative ColitisNCT06231264Xijing Hospital96
已完成
3 期
Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of MigraineMigraineNCT02638103Teva Branded Pharmaceutical Products R&D, Inc.1,890
已完成
不适用
Transcutaneous Electrical Nerve Stimulation Treatment of Renal ColicRenal ColicNCT03237208Adiyaman University Research Hospital100